tirzepatide lawsuit update novo nordisk Nordisk's CagriSema Shows Strong Weight-Loss Results But Trails Eli Lilly's in Latest Clinical Data FDA's tirzepatide decision creates uncertainty

Liu, Y., Hazlewood, G

Kristensen 2012), and kidney toxicity (Bessems 2001)

While it was first approved as Mounjaro for treating type 2 diabetes, it's shown such impressive weight loss results that it's gotten a lot of attention for this use too

Ashley, director of the Office of Compliance in the FDA's Center for Drug Evaluation and Research, said in a press release

That is what we have started this week with tirzepatide. Trial protocols call for half of the 1,000 participants to receive a placebo, inert doses that have no effect, rather than the active drug, creating a control group that is critical to obtaining scientifically valid results